Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

Digital_Intelligence_blog_pharma_thumbBoehringer Ingelheim's work on a web and smartphone programme for diabetes self-management has finally got off the ground with the launch of a US study.

It aims to investigate the effect of a digital diabetes programme on medical and pharmaceutical costs, clinical care and patient behaviour.

Boehringer last year partnered with US digital health management company Healthrageous to evaluate the effects of a combination of digital coaching and wireless glucose meters on glucose control and medication adherence.

Now the company's have teamed up with United BioSource Corporation (UBC), who will identify and help manage the recruitment of type 2 diabetes patients for the study from nearly a dozen large US employers.

The SMART study's digital diabetes self-management programme will involve a personalised action plan with health behaviour improvement goals, a wireless glucose meter transmitting data to clinical monitors and HbA1c at-home test kits.

Klaus Wilgenbus, SVP, PM, business development, licensing and strategy at Boehringer Ingelheim, said: "Boehringer Ingelheim is committed to innovation in diabetes treatment and strives for solutions that offer a 'beyond pill' approach in health care.

"As part of our ongoing collaboration with Healthrageous, this project adds nicely to our goal to provide and develop solutions for patients and their families that contribute to a more holistic way of diabetes treatment."

The ultimate goal of the programme is to leverage technology in a way that makes the personalised journey of self-managing diabetes easier for patients.

Rick Lee, Healthrageous president and CEO, said: "Innovations in machine learning and technology offer the opportunity to create and deliver a unique experience for each person with type 2 diabetes.

"We are delighted to be working with Boehringer Ingelheim and UBC on this first-of-its-kind evaluation of the promise that digital technology holds in stemming the type 2 diabetes epidemic."

For Boehringer the collaboration is part of its drive to explore new technology and services that can be aligned to its commercial medicines business, an increasing focus of which is on diabetes.

It can also be seen as part of a concerted digital push within the therapy area;one that in the last year has encompassed initiatives such as an online diabetes management game, HCP education, online behavioural change and a wireless pill bottle.

18th July 2013

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics